Hantz Financial Services’s NovoCure NVCR Stock Holding History

Hantz Financial Services’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16	Closed	-$1K	–	1099
2021 Q4	$1K	Buy	+16	New	+$1.61K	﹤0.01%	848

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hantz Financial Services's NVCR Position: Q1 2022 in Review

Hantz Financial Services sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 16 shares — an estimated $1K sold.

Hantz Financial Services first reported a position in NVCR in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

Hantz Financial Services reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
Hantz Financial Services sold 16 NovoCure shares in Q1 2022, an estimated $1K.
Hantz Financial Services first reported a position in NovoCure in Q4 2021 and held it in 1 quarter.
Hantz Financial Services's NovoCure position peaked at $1K in Q4 2021.
308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Hantz Financial Services's 13F filing for Q1 2022, filed 23 Aug 2022.